Dogwood Therapeutics, Inc. DWTX
1.16 USD -0.02 (-1.69%)
Nov 12, 2026, 11:13 AM EST
1.15 Day range 1.21
0.901 52-week range 7.04
- YTD
- -72.12%
- 1 year
- -80.10%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Dogwood Therapeutics Q3 EPS $(0.14) Beats $(0.15) Estimate, Sales $100.000K Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 98.29 percent increase over losses of…
globenewswire.com Dogwood Therapeutics Announces Third Quarter 2026 Financial Results - Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 -
benzinga.com Dogwood Therapeutics Enters Into Securities Subscription Agreement For $5 Investment From CK Life Sciences’ Subsidiary - Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 -- Expected Proceeds from the Investment Enable Acceleration of Phase 3…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex…
benzinga.com Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.14) by 142.86 percent. This is a 82.91 percent increase over…
benzinga.com Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
- benzinga.com Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension Trial Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced…
- benzinga.com Dogwood Therapeutics Q1 EPS $(0.15), Inline Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 98.22 percent increase over losses of $(8.45) per share from the…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
benzinga.com Dogwood Therapeutics Partners With PRIDCor Therapeutics To Advance Its Anti-Viral Candidates IMC-1 And IMC-2 Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Dogwood Therapeutics Announces FDA Acceptance Of IND Application For Development Candidate SP16, Administered IV, For Treatment Of Chemotherapy-Induced Pain And Peripheral Neuropathy Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin PharmaThe SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.17) by 77.83 percent. This is a 95.87 percent increase over losses…
benzinga.com HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.- benzinga.com HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
- benzinga.com Dogwood Therapeutics Highlights Pipeline Expansion And Clinical Progress Toward Non-Opioid Cancer Pain And Neuropathy Treatments; Key Halneuron And SP16 Milestones Targeted For 2026 Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following…
- benzinga.com What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026 - Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- The overall study dropout rate of ~4.4% is far below…
- benzinga.com Dogwood Therapeutics Files For New Intellectual Property Protection For Synthetic Halneuron Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new…
- benzinga.com Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade
benzinga.com Dogwood Therapeutics Enrolls First 100 Patients In Ongoing HALT-CINP Phase 2b CINP Trial - Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well toleratedATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 /…- benzinga.com Dogwood Therapeutics Q3 EPS $(8.20) Misses $(1.58) Estimate Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.20) per share which missed the analyst consensus estimate of $(1.58) by 418 percent. This is a 300 percent decrease over losses of…
- benzinga.com Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025 Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - benzinga.com HC Wainwright & Co. Maintains Buy on Dogwood Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Sean Lee maintains Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and raises the price target from $10 to $12.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
- benzinga.com Market-Moving News for September 29th LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced anaphylaxis and were withdrawn from its long-term study evaluating daily subcutaneous injections of
- benzinga.com Dogwood Therapeutics Q2 EPS $(1.99) Misses $(1.90) Estimate Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(1.90) by 4.74 percent. This is a 73.04 percent decrease over losses…
- benzinga.com Dogwood Therapeutics Enrolls First 50 Patients In Ongoing Phase 2b CINP Trial And Remains On Track To Execute Planned Interim Analysis On ~100 Patients Who Will Have Completed Four Week Trial During Q4 Of 2025 - Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track as projected for Q4 2025 -- Low discontinuation rate (6%) due to adverse events…
- benzinga.com Dogwood Therapeutics Q1 EPS $(8.45) Misses $(2.38) Estimate Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.45) per share which missed the analyst consensus estimate of $(2.38) by 255.04 percent. This is a 402.98 percent decrease over…
- benzinga.com HC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target HC Wainwright & Co. analyst Sean Lee upgrades Dogwood Therapeutics (NASDAQ:DWTX) from Neutral to Buy and announces $10 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Dogwood Therapeutics Regains Nasdaq Compliance Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session